Yufei Wang, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of the tumor microenvironment (TME) in the treatment of kidney cancer, in particular for renal cell carcinoma (RCC). Dr Wang outlines the impacts that the TME on novel therapies, including chimeric antigen receptor (CAR) T-cell therapies. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.